|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC5 |
Gene summary for DNAJC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC5 | Gene ID | 80331 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C5 | |
| Gene Alias | CLN4 | |
| Cytomap | 20q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | Q6AHX3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80331 | DNAJC5 | C43 | Human | Oral cavity | OSCC | 1.39e-15 | 3.85e-01 | 0.1704 |
| 80331 | DNAJC5 | C46 | Human | Oral cavity | OSCC | 5.24e-06 | 1.91e-01 | 0.1673 |
| 80331 | DNAJC5 | C51 | Human | Oral cavity | OSCC | 1.88e-24 | 1.00e+00 | 0.2674 |
| 80331 | DNAJC5 | C57 | Human | Oral cavity | OSCC | 2.27e-28 | 8.14e-01 | 0.1679 |
| 80331 | DNAJC5 | C06 | Human | Oral cavity | OSCC | 3.44e-08 | 1.20e+00 | 0.2699 |
| 80331 | DNAJC5 | C08 | Human | Oral cavity | OSCC | 2.39e-09 | 3.22e-01 | 0.1919 |
| 80331 | DNAJC5 | C09 | Human | Oral cavity | OSCC | 5.99e-07 | 2.94e-01 | 0.1431 |
| 80331 | DNAJC5 | LN46 | Human | Oral cavity | OSCC | 1.14e-05 | 3.06e-01 | 0.1666 |
| 80331 | DNAJC5 | LP15 | Human | Oral cavity | LP | 2.26e-04 | 9.35e-01 | 0.2174 |
| 80331 | DNAJC5 | EOLP-1 | Human | Oral cavity | EOLP | 2.25e-02 | 2.29e-01 | -0.0202 |
| 80331 | DNAJC5 | SYSMH1 | Human | Oral cavity | OSCC | 1.74e-13 | 3.69e-01 | 0.1127 |
| 80331 | DNAJC5 | SYSMH2 | Human | Oral cavity | OSCC | 1.64e-12 | 4.89e-01 | 0.2326 |
| 80331 | DNAJC5 | SYSMH3 | Human | Oral cavity | OSCC | 4.85e-28 | 6.79e-01 | 0.2442 |
| 80331 | DNAJC5 | SYSMH5 | Human | Oral cavity | OSCC | 5.83e-13 | 4.22e-01 | 0.0647 |
| 80331 | DNAJC5 | SYSMH6 | Human | Oral cavity | OSCC | 3.42e-04 | 2.47e-01 | 0.1275 |
| 80331 | DNAJC5 | P1_cSCC | Human | Skin | cSCC | 4.62e-17 | 6.03e-01 | 0.0292 |
| 80331 | DNAJC5 | P2_cSCC | Human | Skin | cSCC | 3.53e-08 | 3.55e-01 | -0.024 |
| 80331 | DNAJC5 | P4_cSCC | Human | Skin | cSCC | 2.52e-11 | 3.27e-01 | -0.00290000000000005 |
| 80331 | DNAJC5 | P10_cSCC | Human | Skin | cSCC | 1.41e-14 | 4.73e-01 | 0.1017 |
| 80331 | DNAJC5 | male-WTA | Human | Thyroid | PTC | 4.79e-19 | 2.18e-01 | 0.1037 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00610779 | Cervix | CC | chaperone-mediated protein folding | 21/2311 | 67/18723 | 3.40e-05 | 5.55e-04 | 21 |
| GO:007099710 | Cervix | CC | neuron death | 70/2311 | 361/18723 | 7.50e-05 | 1.03e-03 | 70 |
| GO:190121410 | Cervix | CC | regulation of neuron death | 61/2311 | 319/18723 | 3.11e-04 | 3.31e-03 | 61 |
| GO:00064579 | Cervix | CC | protein folding | 44/2311 | 212/18723 | 3.43e-04 | 3.59e-03 | 44 |
| GO:005140210 | Cervix | CC | neuron apoptotic process | 49/2311 | 246/18723 | 4.48e-04 | 4.48e-03 | 49 |
| GO:00435238 | Cervix | CC | regulation of neuron apoptotic process | 41/2311 | 212/18723 | 2.23e-03 | 1.60e-02 | 41 |
| GO:00068873 | Cervix | CC | exocytosis | 59/2311 | 352/18723 | 8.74e-03 | 4.48e-02 | 59 |
| GO:0070997 | Colorectum | AD | neuron death | 114/3918 | 361/18723 | 1.13e-06 | 3.72e-05 | 114 |
| GO:0006457 | Colorectum | AD | protein folding | 73/3918 | 212/18723 | 3.24e-06 | 9.10e-05 | 73 |
| GO:1901214 | Colorectum | AD | regulation of neuron death | 99/3918 | 319/18723 | 1.26e-05 | 2.76e-04 | 99 |
| GO:0051402 | Colorectum | AD | neuron apoptotic process | 77/3918 | 246/18723 | 8.07e-05 | 1.28e-03 | 77 |
| GO:1901215 | Colorectum | AD | negative regulation of neuron death | 67/3918 | 208/18723 | 8.81e-05 | 1.35e-03 | 67 |
| GO:0061077 | Colorectum | AD | chaperone-mediated protein folding | 26/3918 | 67/18723 | 6.20e-04 | 6.48e-03 | 26 |
| GO:0043523 | Colorectum | AD | regulation of neuron apoptotic process | 64/3918 | 212/18723 | 8.95e-04 | 8.63e-03 | 64 |
| GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
| GO:0099003 | Colorectum | AD | vesicle-mediated transport in synapse | 57/3918 | 200/18723 | 6.53e-03 | 4.06e-02 | 57 |
| GO:0043524 | Colorectum | AD | negative regulation of neuron apoptotic process | 43/3918 | 145/18723 | 8.04e-03 | 4.73e-02 | 43 |
| GO:00709971 | Colorectum | SER | neuron death | 84/2897 | 361/18723 | 5.76e-05 | 1.35e-03 | 84 |
| GO:00064571 | Colorectum | SER | protein folding | 54/2897 | 212/18723 | 1.04e-04 | 2.18e-03 | 54 |
| GO:00514021 | Colorectum | SER | neuron apoptotic process | 60/2897 | 246/18723 | 1.65e-04 | 3.13e-03 | 60 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
| hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
| hsa04141 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
| hsa041411 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
| hsa041412 | Colorectum | SER | Protein processing in endoplasmic reticulum | 60/1580 | 174/8465 | 4.20e-07 | 7.33e-06 | 5.32e-06 | 60 |
| hsa041413 | Colorectum | SER | Protein processing in endoplasmic reticulum | 60/1580 | 174/8465 | 4.20e-07 | 7.33e-06 | 5.32e-06 | 60 |
| hsa041414 | Colorectum | MSS | Protein processing in endoplasmic reticulum | 75/1875 | 174/8465 | 3.78e-10 | 8.44e-09 | 5.17e-09 | 75 |
| hsa041415 | Colorectum | MSS | Protein processing in endoplasmic reticulum | 75/1875 | 174/8465 | 3.78e-10 | 8.44e-09 | 5.17e-09 | 75 |
| hsa041418 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
| hsa041419 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
| hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0414116 | Lung | IAC | Protein processing in endoplasmic reticulum | 37/1053 | 174/8465 | 6.53e-04 | 5.73e-03 | 3.81e-03 | 37 |
| hsa0414117 | Lung | IAC | Protein processing in endoplasmic reticulum | 37/1053 | 174/8465 | 6.53e-04 | 5.73e-03 | 3.81e-03 | 37 |
| hsa0414123 | Lung | AIS | Protein processing in endoplasmic reticulum | 35/961 | 174/8465 | 4.88e-04 | 4.39e-03 | 2.81e-03 | 35 |
| hsa0414133 | Lung | AIS | Protein processing in endoplasmic reticulum | 35/961 | 174/8465 | 4.88e-04 | 4.39e-03 | 2.81e-03 | 35 |
| hsa0414130 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
| hsa04141113 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC5 | SNV | Missense_Mutation | c.112N>T | p.Leu38Phe | p.L38F | Q9H3Z4 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| DNAJC5 | deletion | Frame_Shift_Del | c.94_95delNN | p.Lys33ValfsTer25 | p.K33Vfs*25 | Q9H3Z4 | protein_coding | TCGA-AR-A254-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |||
| DNAJC5 | SNV | Missense_Mutation | novel | c.340N>A | p.Gly114Ser | p.G114S | Q9H3Z4 | protein_coding | tolerated(0.22) | benign(0.341) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DNAJC5 | SNV | Missense_Mutation | c.106C>T | p.Arg36Trp | p.R36W | Q9H3Z4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BI-A0VS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DNAJC5 | SNV | Missense_Mutation | novel | c.128N>G | p.His43Arg | p.H43R | Q9H3Z4 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DNAJC5 | SNV | Missense_Mutation | rs772453351 | c.193N>A | p.Ala65Thr | p.A65T | Q9H3Z4 | protein_coding | tolerated(0.23) | benign(0.015) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| DNAJC5 | SNV | Missense_Mutation | novel | c.283N>A | p.Val95Met | p.V95M | Q9H3Z4 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DNAJC5 | SNV | Missense_Mutation | c.20G>A | p.Arg7His | p.R7H | Q9H3Z4 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DNAJC5 | SNV | Missense_Mutation | c.76N>A | p.Ala26Thr | p.A26T | Q9H3Z4 | protein_coding | deleterious(0.01) | possibly_damaging(0.595) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNAJC5 | SNV | Missense_Mutation | c.473N>T | p.Gln158Leu | p.Q158L | Q9H3Z4 | protein_coding | deleterious(0) | benign(0.218) | TCGA-ED-A459-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Ancillary | alvesin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |